Obsidian Therapeutics

Obsidian Therapeutics

    Company info:

  • 51-100
  • 2015
  • Cambridge, MA
  • 100-500M



Claim company profile

About company:

Obsidian Therapeutics is developing tumor infiltrating lymphocyte (TIL) therapies for patients with intractable diseases. Conventional TIL therapies have had some success for cancer patients but are still limited by toxicity concerns caused by concomitant IL2 therapy. Using their proprietary cytoDRIVE platform, Obsidian is engineering cytoTIL therapies to express therapeutic proteins that enhance anti-tumor activity and reduce toxicity. Obsidian’s lead program, cytoTIL15, has been engineered to eliminate the need for concomitant IL2 therapy improving the magnitude and duration of response. cytoTIL15 will enter clinical trials for patients with metastatic melanoma.


Obsidian Therapeutics
Cell and Gene Therapy Analytics Co-Op (Spring 2024...
Cambridge, MA|7 days ago
Obsidian Therapeutics
Cell Therapy Process Development Co-Op
Cambridge, MA|14 days ago
Obsidian Therapeutics
Cell Therapy, Co-Op
Cambridge, MA|16 days ago
Obsidian Therapeutics
Director, Analytical Development (Viral Vector)
Cambridge, MA|100+ days ago
Obsidian Therapeutics
General Interest Application - Obsidian Talent Com...
Cambridge, MA|100+ days ago

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com